Table 6.
Patient characteristics and pMMA and uMMA values of a subset of individuals from the MARLINA trial. Mean and SD of MMA, eGFR, Age and BMI at V3 and V7 at medium MMA levels.
| Time | Variable | Placebo | Linagliptin | TT | ||
|---|---|---|---|---|---|---|
| n | Mean ± SD | n | Mean ± SD | p | ||
| Plasma | ||||||
| V3 | MMA | 80 | 149.0 ± 57.1 | 80 | 139.0 ± 65.2 | 0.300 |
| eGFR | 78.9 ± 22.8 | 77.9 ± 22.4 | 0.700 | |||
| Age | 60.4 ± 9.2 | 62.4 ± 10.3 | 0.200 | |||
| BMI | 28.8 ± 4.7 | 28.3 ± 4.8 | 0.500 | |||
| V7 | MMA | 162.0 ± 58.9 | 141.0 ± 64.8 | 0.030 | ||
| eGFR | 77.6 ± 24.1 | 75.8 ± 23.0 | 0.600 | |||
| BMI | 28.9 ± 4.9 | 28.3 ± 4.8 | 0.500 | |||
| Urine | ||||||
| V3 | MMA | 77 | 1.3 ± 0.75 | 86 | 1.14 ± 0.77 | 0.200 |
| eGFR | 78.6 ± 21.9 | 81.6 ± 19.8 | 0.300 | |||
| Age | 59.1 ± 9.6 | 60.7 ± 8.9 | 0.300 | |||
| BMI | 27.6 ± 4.1 | 27.7 ± 4.7 | 0.900 | |||
| V7 | MMA | 1.42 ± 0.87 | 1.06 ± 0.58 | 0.003 | ||
| eGFR | 76.7 ± 22.9 | 79.0 ± 20.8 | 0.500 | |||
| BMI | 27.4 ± 4.2 | 27.7 ± 4.7 | 0.700 | |||
eGFR estimated glomerular filtration; MMA methylmalonic acid; SD standard deviation; TT Welch t-test; V3 baseline; V7 end of study.
Significant p values (< 0.05) are in bold. BMI, body mass index.